news
Horizon Europe deal signals UK research reinvigoration
From the 7 September 2023, UK scientists can apply for funding from the largest R&D collaboration programme globally, thus accelerating therapeutic advancement.
List view / Grid view
Association of the British Pharmaceutical Industry (ABPI)
news
Life sciences sector to receive £650 million funding
Funding to support the UK's life sciences manufacturing, skills and infrastructure has been announced as part of a £650m growth package.
news
NICE approves cost-comparison fast-track appraisal pilot
A new approach to the cost-comparison fast-track appraisal process is being piloted this summer for the review of low-risk appraisals.
article
Has the threat of waiving COVID-19 vaccine intellectual property rights had its desired effect?
In this final article on the TRIPS waiver for COVID-19 vaccines, medicines, diagnostics and technologies, EPR’s Hannah Balfour considers whether it is the correct strategy to overcome COVID-19 treatment inequalities and explores other options.
news
British pharma’s 2021 Code of Practice now in force
The ABPI’s 2021 pharmaceutical industry Code of Practice aims to increase transparency, encourage collaboration and improve patient care.
news
Pharma industry employs 5,600 people in Scotland, report says
A new report has shown that the pharmaceutical industry in Scotland employs nine percent more people now than in 2018.
news
British pharma responds to UK’s Chancellor’s new Spending Review
The ABPI has commented on the new Spending Review and outlined ways the UK government can help the life sciences sector.
news
UK leads Europe in Phase I and Phase II trials, ABPI findings show
The ABPI has found that the UK is leading the rest of Europe in early-stage clinical trials and makes suggestions on how the country can maintain this position.
news
Failure to secure ‘bare minimum’ deal on medicines could put patients at risk, MPs told
1 October 2020 | By
UK politicians were warned that without a post-Brexit deal on medicines, short-term supply delays could be damaging to both public health and the economy.
news
UK and EU pharma call for medicines to be prioritised in Brexit trade talks
The ABPI and EFPIA have both emphasised the need for trade talks to mitigate medicine supply chain disruptions following Brexit.
news
British pharma responds to free trade agreement between UK and Japan
The ABPI has said that the new UK-Japan free trade agreement will benefit the pharma industry, providing continuity for life science businesses.
news
British pharma industry responds to new Brexit guidance from MHRA
The ABPI has responded to new guidance, intended to prepare pharma companies for the end of the Brexit transition period, from the MHRA.
news
Global manufacturing “fundamental” for drug supply chain, says ABPI Chief Executive
The ABPI's Dr Richard Torbett, speaking to the International Trade Committee, said the COVID-19 pandemic highlights the need for a globalised drug supply chain.
news
Landmark investment for life sciences in UK government Budget
The UK government has pledged funding of £22 billion per year into R&D by 2025 in its Budget, just days after a further £46 million was invested into coronavirus research.
news
ABPI responds to UK points-based immigration system
The ABPI has outlined how the new immigration system in the UK will affect life science workers and businesses, emphasising the need for regular reviews to remain competitive.
